An observational study in Post COVID-19 Condition (PCC), sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by University Hospital, Basel, Switzerland · Observational
The Basel Long COVID Cohort Study (BALCoS) is a registry-based cohort study that focuses on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved. The project aims to investigate proposed mechanisms behind Post COVID-19 condition (PCC), including a) autoimmunity, b) chronic inflammation, c) genetics, d) coagulation disorders, and e) psychosocial factors. Patients in the cohort can also join the Digital Long COVID Study (DiLCoS), a single-arm, cohort-based proof-of-feasibility study that is part of the larger BALCoS. DiLCoS is a intervention substudy designed to evaluate whether doing exercises delivered via a smartphone app (referred as digital intervention) can help with PCC. The digital intervention is a 12-week program that includes different kinds of exercises like breathing exercises, relaxation techniques, and tips on managing fatigue and other symptoms. It also teaches patients how to monitor their activities and energy levels, and provides psychological exercises to cope with negative thoughts and pain. Patients in the cohort complete a set of assessments that include the collection of sociodemographic and clinical data, biomarkers, neurocognitive testing, psychometric questionnaires, and measures of physical performance, and provide consent that their data from routine clinical care can be used for the study.
1,860 studies on the registry are indexed under Fatigue; 376 are open to participants now.
This study's enrollment of 196 is above the median of 100 across 367 observational studies indexed under Fatigue.
Browse Fatigue studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients will be recruited at the medical outpatient clinic unit at the UHB from April 2023 on. Any patient fulfilling inclusion criteria and lacking exclusion criteria will be asked to participate in the study and the substudy.
Additional Inclusion Criteria for participtation in DiLCoS:
Exclusion Criteria:
Patients of the cohort that are not enrolled in the DiLCoS substudy
Other: Data collection
Patients of the cohort that are additionnaly enrolled in the DiLCoS substudy
Other: Digital intervention (DiLCoS) · Other: Data collection
The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.
Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
Change in World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12- item version)
The World Health Organization Disability Assessment Schedule (WHODAS 2.0) assesses and classifies disability due to health problems during the past 4 weeks. This study will utilize the 12- item version. Items are answered on a 5-point scale ranging from 0 = "none" to 4 = "extreme or cannot do".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in Visual analogue scales (VAS)
Patients will answer 4 questions on a VAS with a rating slider ranging from 0 to 10. The questions will inquire symptom intensity (10 = it can't be worse), functional impairment (10 = can't be worse), quality of life (10 = can't be better), and work capacity (10 = full work capacity).
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in EuroHIS Quality-of-Life-8 (QOL-8)
This 8-item instrument assesses quality of life and perceived health during the past 4 weeks. Items are answered on a 5-point scale, with wording differing between questions (e.g., from "very dissatisfied" to "very satisfied").
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Somatic Symptom Disorder Questionnaire (SSD-12)
SSD-12 assesses psychological features of somatic disorders, e.g. catastrophizing thoughts and health anxiety. Items are answered on a 5-point scale ranging from 0 = "never" to 4 = "very often".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Patient Health Questionnaire (PHQ-15)
PHQ-15 assesses somatic symptom severity during the past 4 weeks. Patients are asked how impaired they felt by their symptoms, e.g. back pain. Items are answered on a 3-point scale ranging from 0 = "not bothered at all" to 2 = "bothered a lot".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Patient Health Questionnaire Depression Scale (PHQ-8)
PHQ-8 assesses the severity of depressive disorders. Patients are asked if in the past weeks, they were bothered by a problem. Items are answered on a 4-point scale ranging from 0 = "not at all" to 3 = "nearly every day".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Generalized Anxiety Disorder Questionnaire (GAD-7)
GAD-7 assesses if the patient was bothered by complaints related to anxiety during the past 2 weeks. Items are answered on a 4-point Likert scale ranging from 0 = "not at all" to 3 = "nearly every day".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Resilience Scale (Resilience Scale (RS-11)
The 11-item RS-11 asks about general resilience towards life events. Items are answered on a 7-point scale ranging from 1 = "strongly agree" to 7 = "strongly disagree".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Insomnia Severity Index (ISI)
Insomnia, e.g. difficulty falling asleep, is assessed by the ISI. Items are answered on a 5-point scale with regards to severity during the past 2 weeks, with wording differing between questions (e.g., from 0 = "very dissatisfied" to 4 = "very satisfied").
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Chalder Fatigue Scale
Fatigue is assessed by the 11-item Chalder Fatigue Scale. Items are answered on a 4-point scale ranging from 0 = "Better than usual" to 3 = "much worse than usual".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in the Perceived Stress Scale (PSS)
The PSS investigates the experience of psychological stress in the past 4 weeks. It consists of 10 items. Items are answered on a 5-point scale ranging from 1 = "never" to 5 = "very often".
Time frame: At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)
Change in JAMAR® grip strength test on the dominant hand
Grip strength will be assessed using the JAMAR®, a hydraulic grip strength measuring device (American Society for Surgery of the Hand, 1983). The test is repeated thrice for the dominant hand. The best value (in kg) is taken.
Time frame: At Baseline and T3 (BL + 12 months)
Change in 6-minute walking test
6-minute walking test is to assess functional exercise capacity by measuring the distance (in meters total) that a patient can walk in 6 minutes. Well-being before and after the test is assessed on a 5-point Likert-scale ranging from 1 = "very bad" to 5 = "very good". After the test, perceived exertion of breathing and legs is assessed with the Borg Category-Ratio (CR) 10 Scale ranging from 0 = "no exertion" to 10 = "maximal exertion"
Time frame: At Baseline and T3 (BL + 12 months)
Change in one minute sit-to-stand test (STS-60)
STS-60 is a measure for muscular endurance. It assesses the number of sit-to-stand cycles that can be achieved within one minute.
Time frame: At Baseline and T3 (BL + 12 months)
Change in neurocognitive status of patients assessed by CNS Vital Signs (CNSVS) test
CNSVS is a computerized neurocognitive test battery that was developed as a routine clinical screening instrument. It consists of seven scientifically valid and reliable neuropsychological tests that normally require an interviewer. The tests are: verbal and visual memory, finger tapping, symbol digit coding, the Stroop Test, a test of shifting attention, and the continuous performance test. The Neurocognition Index reflects the overall or global neurocognitive functioning of the test taker. It is an average or the standard scores for five of the domains (composite memory, psychomotor speed, reaction time, complex attention and cognitive flexibility) that reflect the patient's performance on each assessment. CNS Vital Signs standardized have a mean of 100 and a standard deviation is 15. Higher scores are always better.
Time frame: At Baseline and T3 (BL + 12 months); approximately 40-50 minutes per test battery
(Only BALCoS w/ DiLCoS) Progress and patients' engagement assessed by weekly feedback questions
Patients enrolled in DiLCoS are presented with questions for qualitative feedback at the end of each weekly module within the digital intervention
Time frame: After BL and before T1; at day 6 in weeks 1-11
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland